Table 1.
Baseline characteristics
| Characteristic | Thrombocytopenia, n = 274 | Control, n = 796 |
|---|---|---|
| Sex, male, n (%) | 170 (62.0) | 491 (61.7) |
| Age at diagnosis (median, range), y | 72 (37-95) | 72 (26-96) |
| Concurrent antiplatelet treatment, n (%) | 208 (75.9) | 572 (71.9) |
| Comorbidities, n (%) | ||
| Diabetes | 71 (25.9) | 46 (5.8) |
| Hypertension | 79 (28.8) | 62 (7.8) |
| Heart failure | 99 (36.1) | 67 (8.4) |
| Ischemic heart disease | 140 (51.1) | 80 (10.1) |
| Cancer | 61 (22.3) | 85 (10.7) |
| Chronic kidney disease | 13 (4.7) | 17 (2.1) |
| Cirrhosis | 35 (12.8) | 60 (7.5) |
| Prior stroke | 13 (4.7) | 6 (0.8) |
| Prior bleed | 10 (3.6) | 18 (2.3) |
| Anticoagulant agent, n (%) | ||
| Warfarin | 131 (47.8) | 385 (48.4) |
| DOAC∗ | 143 (52.2) | 411 (51.6) |
| Apixaban | 108 (39.4) | 315 (39.6) |
| Dabigatran | 1 (0.4) | 3 (0.4) |
| Rivaroxaban | 34 (12.4) | 93 (11.7) |
| CHA2DS2-VASc score, n (%) | ||
| 0-2 | 112 (40.9) | 313 (39.3) |
| 3-5 | 149 (54.4) | 442 (55.5) |
| 6-9 | 13 (4.7) | 41 (5.2) |
Baseline characteristics are shown after matching. supplemental Figure 2 shows absolute standardized mean differences for individual variables before and after matching.
DOAC, direct oral anticoagulant.